CDXS vs DHR vs ILMN Stock Comparison

Codexis, Danaher and Illumina Prices as of Nov 4, 2026 Peers: Industry group
1 more company in this comparison (QGEN) Create a free account to keep reading and compare up to 10 companies.
CDXS Codexis, Inc.
$1.08 -22.3% 1M -50.2% 1Y
Market cap
$98.70M
P/E
–
Revenue (TTM)
$77.68M
Div. yield
–
Life Sciences Tools Healthcare
1 win
DHR Danaher Corp /De/
$234.94 +6.2% 1M +9.9% 1Y
Market cap
$165.26B
P/E
38.2x
Revenue (TTM)
$25.61B
Div. yield
0.65%
Life Sciences Tools Healthcare
5 wins
ILMN Illumina, Inc.
$226.54 -22.9% 1M +93.9% 1Y
Market cap
$34.25B
P/E
38.2x
Revenue (TTM)
$4.54B
Div. yield
–
Life Sciences Tools Healthcare
5 wins

Head to Head

11 decided of 12

Danaher leads on 5 of the 12 questions below (Danaher 5, Illumina 5, Codexis 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCDXSDHRILMNLeader
Larger companyMarket capitalisation $98.70M $165.26B $34.25B DHR
Cheaper on earningsLower P/E, profitable companies only -3.2x 38.2x 38.2x DHR
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 25.8x 45.4x DHR
Faster revenue growthRevenue growth, trailing twelve months +35.9% +5.5% +5.8% CDXS
More profitableNet margin, trailing twelve months -39.6% 16.9% 19.7% ILMN
Better return on capitalReturn on invested capital -35.1% 5.8% 16.6% ILMN
Less leveragedLower net debt / EBITDA 0.7x 2.6x 0.4x ILMN
Higher dividend yieldTrailing dividend yield — 0.65% — –
Better 1-year returnPrice return, last 12 months -50.2% +9.9% +93.9% ILMN
Better 5-year returnAnnualised price return, 5 years -51.5%/yr -4.3%/yr -10.6%/yr DHR
Less volatileAnnualised volatility, 1 year 87.5% 30.8% 50.2% DHR
Higher overall scoreMean of the five percentile scores vs peers 45/100 61/100 76/100 ILMN

Percentile Scorecard

CDXSDHRILMN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCDXSDHRILMN
Valuation 43 #132 of 229 71 #67 of 229 59 #94 of 229
Growth 67 #73 of 221 26 #164 of 221 75 #56 of 221
Profitability 43 #120 of 209 86 #31 of 209 99 #4 of 209
Financial Health 30 #168 of 240 48 #126 of 240 61 #94 of 240
Shareholder Returns 43 #84 of 146 72 #41 of 146 84 #24 of 146
Overall 45 61 76
  • CDXS ranked among 248 companies in Medical Devices and Diagnostics
  • DHR ranked among 248 companies in Medical Devices and Diagnostics
  • ILMN ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCDXSDHRILMNSPY
1 month -22.3%+6.2%-22.9% -1.0%
3 months -25.5%+17.7%+13.3% -0.4%
6 months -59.4%+34.3%+58.9% +4.5%
Year to date -33.7%+2.6%+72.7% +12.4%
1 year -50.2%+9.9%+93.9% +13.6%
3 years -44.0%+18.7%+99.2% +76.4%
3 years, per year -17.6%+5.9%+25.8% +20.8%
5 years -97.3%-19.6%-42.9% +63.7%
5 years, per year -51.5%-4.3%-10.6% +10.4%
10 years -76.5%+205.4%+73.0% +267.7%
10 years, per year -13.5%+11.8%+5.6% +13.9%

Risk

MeasureCDXSDHRILMNSPY
Volatility, 1Y 87.5%30.8%50.2% 12.8%
Downside volatility, 1Y 92.9%32.0%49.5% 12.7%
Beta vs S&P 500, 1Y 1.850.500.99 1.00
Return / volatility, 1Y -0.570.321.87 1.06
Max drawdown, 5Y -97.7%-50.8%-82.9% -25.4%
From 52-week high -62.1%-2.9%-22.9% -1.6%
52-week high $2.85$242.05$293.69 $779.14
52-week low $0.98$161.91$114.44 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCDXSDHRILMN
P/E now vs peer median -3.2xmedian 28.5x 38.2xmedian 28.5x 38.2xmedian 28.5x
P/S now vs peer median 1.3xmedian 2.9x 6.5xmedian 2.9x 7.5xmedian 2.9x
EV/EBITDA now vs peer median -4.0xmedian 18.5x 23.7xmedian 18.5x 28.1xmedian 18.5x
P/FCF now vs peer median -8.1xmedian 26.7x 28.9xmedian 26.7x 32.4xmedian 26.7x
P/B now vs peer median 3.0xmedian 2.3x 3.1xmedian 2.3x 10.9xmedian 2.3x
PEG now vs peer median -0.12median 0.93 -4.76median 0.93 0.93median 0.93

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCDXSDHRILMN
Revenue $77.68M $25.61B $4.54B
Gross profit $67.60M $15.01B $3.08B
Operating income -$27.66M $5.22B $960.00M
Net income -$30.72M $4.33B $895.00M
Free cash flow -$12.18M $5.73B $1.06B
R&D $48.74M $1.67B $975.00M
EPS (diluted) $-0.34 $6.13 $5.85
Cash & equivalents $27.17M $5.68B $1.29B
Total debt $40.88M $26.48B $1.79B
Shares (diluted) 91.05M 706.80M 153.00M
Enterprise value -$158.35M $144.92B $28.96B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCDXSDHRILMN
P/E -3.2x 38.2x 38.2x
P/FCF -8.1x 28.9x 32.4x
P/Operating cash flow -9.5x 24.1x 27.8x
P/S 1.3x 6.5x 7.5x
P/B 3.0x 3.1x 10.9x
P/Tangible book 3.0x 5.1x 12.4x
EV/EBITDA -4.0x 23.7x 28.1x
EV/EBIT -3.1x 35.7x 36.2x
EV/Revenue 1.1x 7.3x 7.6x
EV/FCF -7.0x 32.5x 32.8x
EV/Operating cash flow -8.1x 27.1x 28.2x
PEG (3Y EPS CAGR) -0.12 -4.76 0.93

Growth

14 metrics
MetricCDXSDHRILMN
Revenue growth (1Y) 35.9% 5.5% 5.8%
Revenue CAGR (3Y) -7.8% 1.3% -0.7%
Gross profit growth (1Y) 52.4% 3.9% 8.5%
Gross profit CAGR (3Y) -2.6% 1.2% 4.4%
Operating income growth (1Y) 51.7% 13.1% 23.1%
Operating income CAGR (3Y) 22.8% -3.8% 30.0%
Net income growth (1Y) 52.7% 23.6% 27.5%
Net income CAGR (3Y) 18.5% -9.9% 40.9%
EPS growth (1Y) 55.7% 24.8% 28.3%
EPS CAGR (3Y) 26.2% -8.0% 41.3%
Operating cash flow growth (1Y) 83.0% 8.6% 9.6%
Operating cash flow CAGR (3Y) -152.3% -5.3% 47.5%
Free cash flow growth (1Y) 82.0% 14.2% 5.7%
Free cash flow CAGR (3Y) -26.3% -5.8% 126.5%

Profitability

14 metrics
MetricCDXSDHRILMN
Gross margin 87.0% 58.6% 67.9%
EBITDA margin -27.0% 30.7% 27.3%
Operating margin -35.6% 20.4% 21.2%
Pretax margin -39.5% 18.8% 23.3%
Net margin -39.6% 16.9% 19.7%
FCF margin -15.7% 22.4% 23.3%
Operating cash flow margin -13.4% 26.8% 27.1%
Return on equity -80.6% 8.2% 29.9%
Return on assets -24.6% 4.7% 13.3%
Return on invested capital -35.1% 5.8% 16.6%
Return on capital employed -27.3% 6.2% 17.2%
Asset turnover 0.6x 0.3x 0.7x
Cash conversion (OCF / net income) 0.3x 1.6x 1.4x
Stock comp / revenue 9.9% 1.3% 5.9%

Financial Health

11 metrics
MetricCDXSDHRILMN
Debt / assets 34.0% 28.4% 26.3%
Debt / equity 1.2x 0.5x 0.6x
Net debt / EBITDA 0.7x 2.6x 0.4x
Debt / FCF -3.4x 4.6x 1.7x
Liabilities / assets 72.5% 42.5% 53.8%
Equity / assets 27.5% 57.5% 46.2%
Interest coverage – 14.5x 9.8x
Current ratio 3.1x 1.6x 2.6x
Quick ratio 2.9x 1.1x 1.8x
Cash ratio 2.3x 0.6x 1.2x
Altman Z-score -6.27 3.77 7.10

Shareholder Returns

7 metrics
MetricCDXSDHRILMN
Dividend yield – 0.6% –
Net buyback yield -0.3% 0.5% 1.1%
Shareholder yield -0.3% 1.2% 1.1%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCDXSDHRILMN
Forward P/E – 25.8xFY2026 45.4xFY2026
EPS, next fiscal year $-0.37FY2026 $9.11FY2026 $4.99FY2026
EPS growth, next FY – +16.8%FY2026 +3.1%FY2026
EPS growth, the year after – +8.0% +25.7%
Revenue, next fiscal year $77.93MFY2026 $27.01BFY2026 $4.52BFY2026
Revenue growth, next FY +10.7%FY2026 +9.9%FY2026 +4.1%FY2026
Revenue growth, the year after +9.2% -1.9% +12.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCDXSDHRILMN
Held by institutions 71.0% 81.9% 100.0%
Institutions holding 148 2,120 935
Change in shares held, QoQ -2.4% +1.1% +0.0%
Institutions buying 88 842 464
Institutions selling 36 1,015 331
Buyers to sellers 2.44 0.83 1.40

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CDXSDHRILMN
CDXS 1.00 0.07 0.04
DHR 0.07 1.00 0.36
ILMN 0.04 0.36 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CDXS, DHR and ILMN?

Danaher (DHR) is the largest by market capitalisation: Codexis (CDXS) $98.70M, Danaher (DHR) $165.26B, Illumina (ILMN) $34.25B.

Which stock is cheaper, CDXS, DHR and ILMN?

Danaher (DHR) trades on the lowest price-to-earnings ratio (Codexis (CDXS) -3.2x, Danaher (DHR) 38.2x, Illumina (ILMN) 38.2x). On next year's consensus earnings, Danaher (DHR) is cheapest (Danaher (DHR) 25.8x, Illumina (ILMN) 45.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Codexis (CDXS) grew revenue fastest over the trailing twelve months: Codexis (CDXS) +35.9%, Danaher (DHR) +5.5%, Illumina (ILMN) +5.8%.

Which company is more profitable?

Illumina (ILMN) has the highest net margin (Codexis (CDXS) -39.6%, Danaher (DHR) 16.9%, Illumina (ILMN) 19.7%). On return on invested capital, Illumina (ILMN) leads (Codexis (CDXS) -35.1%, Danaher (DHR) 5.8%, Illumina (ILMN) 16.6%).

Which stock has performed better?

Over the past year Illumina (ILMN) returned the most: Codexis (CDXS) -50.2%, Danaher (DHR) +9.9%, Illumina (ILMN) +93.9%. Over five years, Danaher (DHR) compounded fastest (Codexis (CDXS) -51.5%/yr, Danaher (DHR) -4.3%/yr, Illumina (ILMN) -10.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Danaher (DHR) 0.65%. Codexis (CDXS) and Illumina (ILMN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Codexis (CDXS) 87.5%, Danaher (DHR) 30.8%, Illumina (ILMN) 50.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CDXS, DHR and ILMN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Danaher (DHR) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.